Astellas Pharma Inc ADR ALPMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALPMY is a good fit for your portfolio.
News
-
Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review
-
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
-
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
-
University of Tsukuba and Astellas Confirm a Strategic Partnership
-
Astellas to Acquire Propella Therapeutics
-
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
-
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
Trading Information
- Previous Close Price
- $12.16
- Day Range
- $11.75–12.28
- 52-Week Range
- $11.25–16.91
- Bid/Ask
- $12.20 / $12.29
- Market Cap
- $22.06 Bil
- Volume/Avg
- 149,640 / 253,425
Key Statistics
- Price/Earnings (Normalized)
- 16.84
- Price/Sales
- 2.03
- Dividend Yield
- 1.76%
- Dividend Yield (Forward)
- 1.76%
- Total Yield
- 3.74%
Company Profile
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 14,484
- Website
- http://www.astellas.com
Valuation
|
Metric
|
ALPMY
|
|---|---|
Price/Earnings (Normalized) | 16.84 |
Price/Book Value | 2.01 |
Price/Sales | 2.03 |
Price/Cash Flow | 10.57 |
Price/Earnings
ALPMY
Financial Strength
|
Metric
|
ALPMY
|
|---|---|
Quick Ratio | 0.75 |
Current Ratio | 0.96 |
Interest Coverage | 6.50 |
Quick Ratio
ALPMY
Profitability
|
Metric
|
ALPMY
|
|---|---|
Return on Assets (Normalized) | 3.03% |
Return on Equity (Normalized) | 5.30% |
Return on Invested Capital (Normalized) | 4.16% |
Return on Assets
ALPMY
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
LLY
| Eli Lilly and Co | Klb | $554.4 Bil | |
JNJ
| Johnson & Johnson | Lywd | $381.3 Bil | |
MRK
| Merck & Co Inc | Pnh | $262.2 Bil | |
ABBV
| AbbVie Inc | Jddfjw | $253.2 Bil | |
RHHBY
| Roche Holding AG ADR | Llp | $220.7 Bil | |
NVS
| Novartis AG ADR | Qgrwm | $200.9 Bil | |
AZN
| AstraZeneca PLC ADR | Mpt | $200.7 Bil | |
PFE
| Pfizer Inc | Jvgw | $163.2 Bil | |
AMGN
| Amgen Inc | Ffp | $145.8 Bil | |
SNY
| Sanofi SA ADR | Qgp | $118.0 Bil |